| Name | Title | Contact Details |
|---|
Nationally-renowned drug & alcohol addiction treatment provider delivering compassionate care through detox, residential/outpatient & virtual programs.
Alivation puts you and your family`s health and well-being first. We do this by investing in the latest medical advancements and meticulously staffing the foremost experts in our industry. From basic behavioral health and family health services to in-depth treatments via transcranial magnetic stimulation therapy (TMS) and brain network monitoring, Alivation`s world-class facility and personal approach to your care is second to none. With a full-service pharmacy and research team on-site, Alivation is the only integrated healthcare clinic in the area that`s large enough to provide a high standard of unique care while being small enough to know our patients on a personal level.
HFS Consultants is a Oakland, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The National Quality Forum (NQF) is the nation`s resource for healthcare quality measurement and improvement. NQF is an independent, not-for-profit, membership-based organization that brings healthcare stakeholders together to recommend quality measures and improvement strategies that reduce costs and help patients get better care. NQF`s membership consists of more than 400 organizations that represent physicians, nurses, hospitals, healthcare systems, patients, families, health plans, employers, and others committed to healthcare quality. Through its multistakeholder membership, NQF facilitates an open and thorough dialogue on healthcare measurement and improvement, and leads national collaboration to improve health and healthcare quality for all Americans.
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.